In a subsequent multivariate analysis, PD-L1 expression (TPS ≥ 50%) remained a negative prognostic factor for the clinical efficacy of second-generation ALK-TKIs in ALK-rearranged NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.